Results of both late breaking trials presented at Heart
Failure 2013
Serelaxin may be more effective for relieving dyspnea in
heart failure with preserved ejection fraction (HFpEF) than reduced (HFrEF)
during the first 24 hours, according to results from RELAX-AHF presented in
today’s late breaking trial session(1) at the Heart Failure Congress 2013.
Results were also presented from VIVIDD, the first trial of the anti-diabetes
drug vildagliptin in patients with heart failure(2).
The Heart Failure Congress is the main annual meeting of the
Heart Failure Association of the European Society of Cardiology and is being held
25-28 May in Lisbon, Portugal.